Sanofi, Boehringer Ingelheim test key immunology drugs in new scleroderma trial

Over three decades of investing, Luke Evnin has backed and advised dozens of biotechs developing medicines. Now, the longtime VC is turning his know-how and industry contacts loose on his own rare disease.

The result is a first-of-its-kind Phase IIb trial in scleroderma, with the study recently winning the FDA’s…
Click here to view original post